{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:02:30Z","timestamp":1775048550946,"version":"3.50.1"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Helsinki including Helsinki University Central Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In the pathogenesis of severe COVID-19 complications, derangements of renin\u2013angiotensin\u2013aldosterone system (RAAS), vascular endothelial dysfunction leading to inflammation and coagulopathy, and arrhythmias play an important role. Therefore, it is worth considering the use of currently available drugs to protect COVID-19 patients with cardiovascular diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We review the current experience of conventional cardiovascular drugs [angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins] as well as some other drug classes (antidiabetic drugs, vitamin D and NSAIDs) frequently used by older patients with cardiovascular diseases. Data were sought from clinical databases for COVID-19 and appropriate key words. Conclusions and recommendations are based on a consensus among all authors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Several cardiovascular drugs have a potential to protect patients with COVID-19, although evidence is largely based on retrospective, observational studies. Despite propensity score adjustments used in many analyses observational studies are not equivalent to randomised controlled trials (RCTs). Ongoing RCTs include treatment with antithrombotics, pulmonary vasodilators, RAAS-related drugs, and colchicine. RCTs in the acute phase of COVID-19 may not, however, recognise the benefits of long term anti-atherogenic therapies, such as statins.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Most current cardiovascular drugs can be safely continued during COVID-19. Some drug classes may even be protective. Age-specific data are scarce, though, and conditions which are common in older patients (frailty, comorbidities, polypharmacy) must be individually considered for each drug group.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s41999-021-00504-5","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:27:42Z","timestamp":1621902462000},"page":"725-739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications"],"prefix":"10.1007","volume":"12","author":[{"given":"Mariana","family":"Alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00edlia Andreia","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fclistan","family":"Bahat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanase","family":"Benetos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Grodzicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Mart\u00ednez-Sell\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Mattace-Raso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakravarthi","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo E.","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"EuGMS Special Interest Group in Cardiovascular Medicine (Chairpersons A. Ungar and A. Benetos)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Grodzicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"504_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26811","author":"D Kheirabadi","year":"2021","unstructured":"Kheirabadi D, Haddad F, Mousavi-Roknabadi RS, Rezaeisadrabadi M, Dehghan H, Fazlzadeh A (2021) A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. J Med Virol. https:\/\/doi.org\/10.1002\/jmv.26811","journal-title":"J Med Virol"},{"key":"504_CR2","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/eurheartj\/ehaa623","volume":"41","author":"P Libby","year":"2020","unstructured":"Libby P, L\u00fcscher T (2020) COVID-19 is, in the end, an endothelial disease. Eur Heart J 41:3038\u20133044","journal-title":"Eur Heart J"},{"key":"504_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ahj.2020.10.065","volume":"232","author":"AS Varshney","year":"2021","unstructured":"Varshney AS, Wang DE, Bhatt AS et al (2021) Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus disease 2019 registered on ClinicalTrials.gov: a cross sectional analysis. Am Heart 232:105\u2013115. https:\/\/doi.org\/10.1016\/j.ahj.2020.10.065","journal-title":"Am Heart"},{"issue":"1","key":"504_CR4","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/VB-20-0014","volume":"3","author":"L Monteonofrio","year":"2020","unstructured":"Monteonofrio L, Florio MC, Al Ghatrif M, Lakatta EG, Capogrossi MC (2020) Aging- and gender-related modulation of RAAS: potential implications in COVID-19 disease. Vasc Biol 3(1):R1\u2013R14. https:\/\/doi.org\/10.1530\/VB-20-0014 (eCollection 2021)","journal-title":"Vasc Biol"},{"issue":"77","key":"504_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jacc.2020.09.617","volume":"2","author":"ED Michos","year":"2021","unstructured":"Michos ED, Cainzos-Achirica M, Heravi AS et al (2021) Vitamin D, calcium supplements, and implications for cardiovascular health: JACC focus seminar. J Am Coll Cardiol 2(77):437\u2013449. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.617","journal-title":"J Am Coll Cardiol"},{"key":"504_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2020.1849193","author":"N Parsamanesh","year":"2020","unstructured":"Parsamanesh N, Pezeshgi A, Hemmati M, Jameshorani M, Saboory E (2020) Neurological manifestations of Coronavirus infections: role of angiotensin-converting enzyme 2 in COVID-19. Int J Neurosci. https:\/\/doi.org\/10.1080\/00207454.2020.1849193","journal-title":"Int J Neurosci"},{"issue":"271\u2013280","key":"504_CR7","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(271\u2013280):e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"key":"504_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","volume":"17","author":"M Nishiga","year":"2020","unstructured":"Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC (2020) COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 17:543\u2013558. https:\/\/doi.org\/10.1038\/s41569-020-0413-9","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"504_CR9","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8(4):e21. https:\/\/doi.org\/10.1016\/S2213-2600(20)30116-8","journal-title":"Lancet Respir Med"},{"key":"504_CR10","unstructured":"de Simone G. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers. https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed 2 Dec 2020"},{"key":"504_CR11","unstructured":"The Renal Association, UK position statement on COVID-19 and ACE inhibitor\/angiotensin receptor blocker use. https:\/\/renal.org\/health-professionals\/covid-19\/ra-resources\/renal-association-uk-position-statement-covid-19-and-ace"},{"key":"504_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1590\/2175-8239-JBN-2020-S112","volume":"42","author":"CIS Rodrigues","year":"2020","unstructured":"Rodrigues CIS (2020) Position paper of the department of hypertension of the Brazilian Society of Nephrology: use of renin-angiotensin system blockers during the course of Covid-19 infection. J Bras Nefrol 42:47\u201348. https:\/\/doi.org\/10.1590\/2175-8239-JBN-2020-S112","journal-title":"J Bras Nefrol"},{"key":"504_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2147\/CIA.S261516","volume":"15","author":"J Sie\u0144ko","year":"2020","unstructured":"Sie\u0144ko J, Kotowski M, Bogacz A et al (2020) COVID-19: the influence of ACE genotype and ACE-I and ARBs on the course of SARS-CoV-2 infection in elderly patients. Clin Interv Aging 15:1231\u20131240. https:\/\/doi.org\/10.2147\/CIA.S261516","journal-title":"Clin Interv Aging"},{"key":"504_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Macedo AVS, de Barros E, Silva PGM et al (2021) Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA 325:254\u2013264","journal-title":"JAMA"},{"key":"504_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2020.10.015","author":"L Ren","year":"2020","unstructured":"Ren L, Yu S, Xu W, Overton JL, Chiamvimonvat N, Thai PN (2020) Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis. J Cardiol. https:\/\/doi.org\/10.1016\/j.jjcc.2020.10.015","journal-title":"J Cardiol"},{"key":"504_CR16","doi-asserted-by":"publisher","first-page":"100627","DOI":"10.1016\/j.ijcha.2020.100627","volume":"31","author":"D Caldeira","year":"2020","unstructured":"Caldeira D, Alves M, Gouveia E, Melo R et al (2020) Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: systematic review and meta-analysis. Int J Cardiol Hear Vasc 31:100627. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100627","journal-title":"Int J Cardiol Hear Vasc"},{"key":"504_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/jcpt.13246","volume":"45","author":"J Barochiner","year":"2020","unstructured":"Barochiner J, Mart\u00ednez R (2020) Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis. J Clin Pharm Ther 45:1244\u20131252. https:\/\/doi.org\/10.1111\/jcpt.13246","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"504_CR18","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/openhrt-2020-001353","volume":"7","author":"AE Ssentongo","year":"2020","unstructured":"Ssentongo AE, Ssentongo P, Heilbrunn ES et al (2020) Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. Open Heart 7(2):1353. https:\/\/doi.org\/10.1136\/openhrt-2020-001353","journal-title":"Open Heart"},{"key":"504_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-020-00211-0","author":"P Namsolleck","year":"2020","unstructured":"Namsolleck P, Moll GN (2020) Does activation of the protective renin-angiotensin system have therapeutic potential in COVID-19? Mol Med. https:\/\/doi.org\/10.1186\/s10020-020-00211-0","journal-title":"Mol Med"},{"key":"504_CR20","unstructured":"ClinicalTrials.gov. Coronavirus (COVID-19) ACEi\/ARB investigation (CORONACION). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04330300. Accessed 12 Dec 2020"},{"key":"504_CR21","unstructured":"ClinicalTrials.gov. Elimination or prolongation of ACE inhibitors and ARB in Coronavirus disease 2019 (REPLACECOVID). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04338009. Accessed 12 Dec 2020"},{"key":"504_CR22","unstructured":"ClinicalTrials.gov. Stopping ACE-inhibitors in COVID-19 (ACEI-COVID). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04353596. Accessed 12 Dec 2020"},{"key":"504_CR23","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W et al (2018) 2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology (ESC) and the European society of hypertension (ESH). Eur Heart J 39:3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"504_CR24","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","volume":"395","author":"FJ de Abajo","year":"2020","unstructured":"de Abajo FJ, Rodr\u00edguez-Mart\u00edn S, Lerma V et al (2020) Use of renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet 395:1705\u20131714. https:\/\/doi.org\/10.1016\/S0140-6736(20)31030-8","journal-title":"Lancet"},{"key":"504_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.18087\/cardio.2020.8.n1307","volume":"60","author":"VY Mareev","year":"2020","unstructured":"Mareev VY, Orlova YA, Pavlikova EP, Matskeplishvili ST, Akopyan ZA, Plisyk AG (2020) Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial \u201cBromhexIne and Spironolactone for Coronavirus Infection requiring hospitalization (BISCUIT).\u201d Kardiologiya 60:4\u201315. https:\/\/doi.org\/10.18087\/cardio.2020.8.n1307","journal-title":"Kardiologiya"},{"key":"504_CR26","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129\u20132200m. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"504_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228612","author":"A Bellis","year":"2020","unstructured":"Bellis A, Mauro C, Barbato E, Trimarco B, Morisco C (2020) The rationale for angiotensin receptor neprilysin inhibitors in a multi-targeted therapeutic approach to COVID-19. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21228612","journal-title":"Int J Mol Sci"},{"key":"504_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ehjcvp\/pvaa028","volume":"6","author":"D Acanfora","year":"2020","unstructured":"Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G (2020) Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril\/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur Hear J-Cardiovasc Pharmacother 6:135\u2013136. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa028","journal-title":"Eur Hear J-Cardiovasc Pharmacother"},{"key":"504_CR29","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1403285","volume":"371","author":"DF McAuley","year":"2014","unstructured":"McAuley DF, Laffey JG, O\u2019Kane CM et al (2014) Simvastatin in the acute respiratory distress syndrome. N Engl J Med 371:1695\u20131703","journal-title":"N Engl J Med"},{"key":"504_CR30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","volume":"6","author":"CS Caffee","year":"2018","unstructured":"Caffee CS, Delucchi KL, Sinha P et al (2018) ARDS subphenotypes and differential response to simvastatin: secondary analysis of a randomized controlled trial. Lancet Respir Med 6:691\u2013698","journal-title":"Lancet Respir Med"},{"key":"504_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S2213-8587(20)30271-0","volume":"8","author":"N Holman","year":"2020","unstructured":"Holman N, Knighton P, Kar P, O\u2019Keefe J, Curley M, Weaver A (2020) Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 8:823\u2013833","journal-title":"Lancet Diabetes Endocrinol"},{"key":"504_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.36469\/jheor.2020.17331","volume":"7","author":"PJ Mallow","year":"2020","unstructured":"Mallow PJ, Belk KW, Topmiller M, Hooker EA (2020) Outcomes of hospitalized COVID-19 patients by risk factors: results from a United States hospital claims database. J Health Econ Outcomes Res 7:165\u2013174","journal-title":"J Health Econ Outcomes Res"},{"key":"504_CR33","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1161\/ATVBAHA.120.315551","volume":"41","author":"HY Lee","year":"2021","unstructured":"Lee HY, Ahn J, Park J et al (2021) Beneficial effect of statins in COVID-19\u2013related outcomes\u2014brief report a national population-based cohort study. Arterioscler Thromb Vasc Biol 41:e175\u2013e182. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315551","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"504_CR34","first-page":"10","volume":"2020","author":"JH Butt","year":"2020","unstructured":"Butt JH, Gerds TA, Schou M, Kragholm K, Phelps H-B (2020) Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. BMJ Open 2020:10","journal-title":"BMJ Open"},{"issue":"176\u201387","key":"504_CR35","first-page":"e4","volume":"32","author":"XJ Zhang","year":"2020","unstructured":"Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y (2020) In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab 32(176\u201387):e4","journal-title":"Cell Metab"},{"key":"504_CR36","doi-asserted-by":"publisher","first-page":"e018475","DOI":"10.1161\/JAHA.120.018475","volume":"9","author":"O Saeed","year":"2020","unstructured":"Saeed O, Castagna F, Agalliu I, Xue X, Patel SR, Rochlani Y (2020) Statin use and in-hospital mortality in diabetics with COVID-19. J Am Heart Assoc 9:e018475","journal-title":"J Am Heart Assoc"},{"key":"504_CR37","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","volume":"180","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G (2020) Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy. Italy JAMA Intern Med 180:1345\u20131355","journal-title":"Italy JAMA Intern Med"},{"key":"504_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01498-x","author":"JD Torres-Pena","year":"2021","unstructured":"Torres-Pena JD, Perez-Belmonte LM, Fuentes-Jimenez F et al (2021) Prior treatment with statins is associated with improved outcomes of patients with COVID-19: data from the SEMI-COVID-19 Registry. Drugs. https:\/\/doi.org\/10.1007\/s40265-021-01498-x","journal-title":"Drugs"},{"key":"504_CR39","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-56210\/v1","author":"A Gupta","year":"2020","unstructured":"Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA, Redfors B (2020) Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-56210\/v1","journal-title":"Res Sq"},{"key":"504_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.06.007","author":"A Lala","year":"2020","unstructured":"Lala A, Johnson KW, Januzzi JL et al (2020) Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Amer Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2020.06.007","journal-title":"J Amer Coll Cardiol"},{"issue":"20","key":"504_CR41","doi-asserted-by":"publisher","first-page":"30153","DOI":"10.1016\/j.diabet.2020.10.001","volume":"S1262\u20133636","author":"B Cariou","year":"2020","unstructured":"Cariou B, Goronflot T, Rimbert A, Boullu S, Le May C, Moulin P (2020) Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: results from the CORONADO study. Diabetes Metab S1262\u20133636(20):30153\u201330161. https:\/\/doi.org\/10.1016\/j.diabet.2020.10.001","journal-title":"Diabetes Metab"},{"key":"504_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa128","author":"L Masana","year":"2020","unstructured":"Masana L, Correig E, Rodriguez-Borjabad C, Anoro E, Arroyo JA, Jerico C (2020) Effect of statin therapy on Sars-Cov-2 infection-related mortality in hospitalized patients. Eur Heart J Cardiovasc Pharmacother. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa128","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"504_CR43","doi-asserted-by":"publisher","first-page":"584870","DOI":"10.3389\/fmed.2020.584870","volume":"17","author":"Y Fan","year":"2020","unstructured":"Fan Y, Guo T, Yan F et al (2020) Association of statin use with the in-hospital outcomes of 2019-coronavirus disease patients: a retrospective study. Front Med (Lausanne) 17(7):584870. https:\/\/doi.org\/10.3389\/fmed.2020.584870","journal-title":"Front Med (Lausanne)"},{"key":"504_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2021.02.002","author":"ZA Yetmar","year":"2021","unstructured":"Yetmar ZA, Challener DW, Tleyjeh IM et al (2021) Association between chronic statin use and 30\u00a0day mortality in hospitalized patients with COVID-19. Mayo Clin Proc Innov Qual Outcomes. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2021.02.002","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"504_CR45","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.14.20194670.Preprint","author":"CJ Nicholson","year":"2020","unstructured":"Nicholson CJ, Wooster L, Sigurslid HH et al (2020) Estimating risk of mechanical ventilation and mortality among adult COVID-19 patients admitted to mass general Brigham: the VICE and DICE scores. medRxiv. https:\/\/doi.org\/10.1101\/2020.09.14.20194670.Preprint","journal-title":"medRxiv"},{"issue":"21","key":"504_CR46","doi-asserted-by":"publisher","first-page":"00053","DOI":"10.1016\/j.jacl.2021.03.002","volume":"S1933\u20132874","author":"P Lohia","year":"2021","unstructured":"Lohia P, Kapur S, Benjaram S, Mir T (2021) Association between antecedent statin use and severe disease outcomes in COVID-19: a retrospective study with propensity score matching. J Clin Lipidol S1933\u20132874(21):00053\u201300062. https:\/\/doi.org\/10.1016\/j.jacl.2021.03.002","journal-title":"J Clin Lipidol"},{"key":"504_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2021.01.009","author":"A Aparisi","year":"2021","unstructured":"Aparisi A, Amat-Santos IJ, Otero DL, Marcos-Mangas M, Gonzalez-Juanatey JR, San Roman JA (2021) Impact of statins in patients with COVID-19. Rev Esp Cardiol. https:\/\/doi.org\/10.1016\/j.recesp.2021.01.009","journal-title":"Rev Esp Cardiol"},{"key":"504_CR48","doi-asserted-by":"publisher","first-page":"17458","DOI":"10.1038\/s41598-020-74492-0","volume":"10","author":"WYT Tan","year":"2020","unstructured":"Tan WYT, Young BE, Chien Lye D, Chew DEK, Dalan R (2020) Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep 10:17458","journal-title":"Sci Rep"},{"key":"504_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-020-02550-8","volume":"20","author":"M Bifulco","year":"2020","unstructured":"Bifulco M, Ciccarelli M, Bruzzese D, Dipasquale A, Lania AG, Mazziotti G (2020) The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed. Endocrine 20:1\u20133. https:\/\/doi.org\/10.1007\/s12020-020-02550-8","journal-title":"Endocrine"},{"key":"504_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1620\/tjem.252.73","volume":"252","author":"NM Alamdari","year":"2020","unstructured":"Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A (2020) Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. Tohoku J Exp Med 252:73\u201384","journal-title":"Tohoku J Exp Med"},{"issue":"21","key":"504_CR51","doi-asserted-by":"publisher","first-page":"00089","DOI":"10.1016\/j.amjms.2021.03.001","volume":"S0002\u20139629","author":"SR Chacko","year":"2021","unstructured":"Chacko SR, DeJoy R 3rd, Lo KB et al (2021) Association of pre-admission statin use with reduced in-hospital mortality in COVID-19. Am J Med Sci S0002\u20139629(21):00089\u201300096. https:\/\/doi.org\/10.1016\/j.amjms.2021.03.001","journal-title":"Am J Med Sci"},{"key":"504_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaa149","author":"A Soleimani","year":"2020","unstructured":"Soleimani A, Kazemian S, Karbalai SS, Aminorroaya A, Shajari Z, Hadadi A (2020) Effects of angiotensin receptor blockers (ARBs) on in-hospital outcomes of patients with hypertension and confirmed or clinically suspected COVID-19. Am J Hypertens. https:\/\/doi.org\/10.1093\/ajh\/hpaa149","journal-title":"Am J Hypertens"},{"key":"504_CR53","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3390\/pathogens9090759","volume":"9","author":"SL Song","year":"2020","unstructured":"Song SL, Hays SB, Panton CE, Mylona EK, Kalligeros M, Shehadeh F (2020) Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: a preliminary study. Pathogens 9:759","journal-title":"Pathogens"},{"key":"504_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.amjcard.2020.09.012","volume":"136","author":"LB Daniels","year":"2020","unstructured":"Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J (2020) Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol 136:149\u2013155","journal-title":"Am J Cardiol"},{"key":"504_CR55","doi-asserted-by":"publisher","first-page":"110005","DOI":"10.1016\/j.jclinane.2020.110005","volume":"67","author":"S Krishnan","year":"2020","unstructured":"Krishnan S, Patel K, Desai R, Sule A, Paik P, Miller A (2020) Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia. J Clin Anesth 67:110005. https:\/\/doi.org\/10.1016\/j.jclinane.2020.110005","journal-title":"J Clin Anesth"},{"key":"504_CR56","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13054-020-03154-4","volume":"24","author":"G Rodriguez-Nava","year":"2020","unstructured":"Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Chung CW, Trelles-Garcia VP, Friedman HJ (2020) Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care 24:429","journal-title":"Crit Care"},{"key":"504_CR57","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s11739-020-02504-y","volume":"15","author":"R Rossi","year":"2020","unstructured":"Rossi R, Talarico M, Coppi F, Boriani G (2020) Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. Intern Emerg Med 15:1573\u20131576","journal-title":"Intern Emerg Med"},{"key":"504_CR58","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.diabet.2021.101250","volume":"17","author":"TE Strandberg","year":"2021","unstructured":"Strandberg TE, Kivim\u00e4ki M (2021) Increased mortality risk associated with statins in the CORONADO study. Diabetes Metab 17:101250. https:\/\/doi.org\/10.1016\/j.diabet.2021.101250","journal-title":"Diabetes Metab"},{"key":"504_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2020.07.101220","author":"AJ Scheen","year":"2020","unstructured":"Scheen AJ (2020) Statins and clinical outcomes with COVID-19: meta-analyses of observational studies. Diabetes Metab. https:\/\/doi.org\/10.1016\/j.diabet.2020.07.101220","journal-title":"Diabetes Metab"},{"key":"504_CR60","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jamda.2020.06.018","volume":"21","author":"A De Spiegeleer","year":"2020","unstructured":"De Spiegeleer A, Bronselaer A, Teo JT et al (2020) The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents. J Am Med Dir Assoc 21:909","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"504_CR61","doi-asserted-by":"publisher","first-page":"iqaa001","DOI":"10.1093\/oxfimm\/iqaa001","volume":"1","author":"NM Schmidt","year":"2020","unstructured":"Schmidt NM, Wing PAC, McKeating JA, Maini MK (2020) Cholesterol-modifying drugs in COVID-19. Oxf Open Immunol 1(1):iqaa001. https:\/\/doi.org\/10.1093\/oxfimm\/iqaa001","journal-title":"Oxf Open Immunol"},{"key":"504_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/08923973.2020.1863984","volume":"43","author":"T Kashour","year":"2021","unstructured":"Kashour T, Halwani R, Arabi YM et al (2021) Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility. Immunopharmacol Immunotoxicol 43:37\u201350. https:\/\/doi.org\/10.1080\/08923973.2020.1863984 (Epub 2021 Jan 6)","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"504_CR63","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/ageing\/afz138","volume":"49","author":"K Luotola","year":"2020","unstructured":"Luotola K, Jyv\u00e4korpi S, Urtamo A, Pitk\u00e4l\u00e4 KH, Kivim\u00e4ki M, Strandberg TE (2020) Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort. Age Ageing 49:258\u2013263","journal-title":"Age Ageing"},{"key":"504_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa126","author":"F Rea","year":"2020","unstructured":"Rea F, Mancia G, Corrao G (2020) Statin\u00a0treatment reduces the risk of death among elderly frail patients: evidence from a large population-based cohort. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa126","journal-title":"Eur J Prev Cardiol"},{"key":"504_CR65","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s40265-020-01365-1","volume":"80","author":"V Bianconi","year":"2020","unstructured":"Bianconi V, Violi F, Fallarino F, Pignatelli P, Sahebkar A, Pirro M (2020) Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19? Drugs 80:1383\u20131396","journal-title":"Drugs"},{"key":"504_CR66","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/CIRCULATIONAHA.120.047830","volume":"142","author":"PA Gurbel","year":"2020","unstructured":"Gurbel PA, Bliden KP, Schr\u00f6r K (2020) Can an old ally defeat a new enemy? Circulation 142:315\u2013317","journal-title":"Circulation"},{"key":"504_CR67","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000005292","author":"JH Chow","year":"2020","unstructured":"Chow JH, Khanna AK, Kethireddy S et al (2020) Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19. Anesth Analg. https:\/\/doi.org\/10.1213\/ANE.0000000000005292","journal-title":"Anesth Analg"},{"key":"504_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26102","author":"ML Meizlish","year":"2021","unstructured":"Meizlish ML, Goshua G, Liu Y et al (2021) Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26102","journal-title":"Am J Hematol"},{"issue":"21","key":"504_CR69","doi-asserted-by":"publisher","first-page":"00003","DOI":"10.1016\/j.amjcard.2020.12.073","volume":"S0002\u20139149","author":"HM Salah","year":"2021","unstructured":"Salah HM, Mehta JL (2021) Meta-analysis of the effect of aspirin on mortality in COVID-19. Am J Cardiol S0002\u20139149(21):00003\u201300005. https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.073","journal-title":"Am J Cardiol"},{"key":"504_CR70","doi-asserted-by":"publisher","first-page":"e23365","DOI":"10.1097\/MD.0000000000023365","volume":"99","author":"AE Tsantes","year":"2020","unstructured":"Tsantes AE, Frantzeskaki F, Tsantes AG et al (2020) The haemostatic profile in critically ill COVID-19 patients receiving therapeutic anticoagulant therapy: an observational study. Medicine (Baltimore) 99:e23365","journal-title":"Medicine (Baltimore)"},{"issue":"20","key":"504_CR71","doi-asserted-by":"publisher","first-page":"35146","DOI":"10.1016\/j.chest.2020.11.005","volume":"S0012\u20133692","author":"D Jim\u00e9nez","year":"2020","unstructured":"Jim\u00e9nez D, Garc\u00eda-Sanchez A, Rali P et al (2020) Incidence of VTE and bleeding among hospitalized patients with Coronavirus disease 2019: a systematic review and meta-analysis. Chest S0012\u20133692(20):35146\u201335151. https:\/\/doi.org\/10.1016\/j.chest.2020.11.005 (Epub ahead of print)","journal-title":"Chest"},{"key":"504_CR72","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.eclinm.2020.100639","volume":"29\u201330","author":"MB Malas","year":"2020","unstructured":"Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clay B (2020) Thromboembolism risk of Covid-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine 29\u201330:100639","journal-title":"EClinicalMedicine"},{"issue":"2","key":"504_CR73","doi-asserted-by":"publisher","first-page":"00260","DOI":"10.1183\/23120541.00260-2020","volume":"6","author":"S Vidali","year":"2020","unstructured":"Vidali S, Morosetti D, Cossu E et al (2020) D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review. ERJ Open Res 6(2):00260\u201302020. https:\/\/doi.org\/10.1183\/23120541.00260-2020","journal-title":"ERJ Open Res"},{"key":"504_CR74","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","volume":"75","author":"Bikdeli B, Madhavan MV, Jimenez D, et al; Global COVID-19 Thrombosis Collaborative Group","year":"2020","unstructured":"Bikdeli B, Madhavan MV, Jimenez D, et al; Global COVID-19 Thrombosis Collaborative Group (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol 75:2950\u20132973. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.031","journal-title":"J Am Coll Cardiol"},{"key":"504_CR75","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/jth.14929","volume":"18","author":"AC Spyropoulos","year":"2020","unstructured":"Spyropoulos AC, Levy JH, Ageno W et al (2020) Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 18:1859\u20131865. https:\/\/doi.org\/10.1111\/jth.14929","journal-title":"J Thromb Haemost"},{"key":"504_CR76","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","volume":"158","author":"LK Moores","year":"2020","unstructured":"Moores LK, Tritschler T, Brosnahan S et al (2020) Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest 158:1143\u20131163. https:\/\/doi.org\/10.1016\/j.chest.2020.05.559","journal-title":"Chest"},{"key":"504_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02331-1","author":"S Testa","year":"2020","unstructured":"Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A (2020) Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med. https:\/\/doi.org\/10.1007\/s11739-020-02331-1","journal-title":"Intern Emerg Med"},{"key":"504_CR78","doi-asserted-by":"publisher","first-page":"e2180","DOI":"10.1002\/rmv.2180","volume":"6","author":"AM Kamel","year":"2020","unstructured":"Kamel AM, Sobhy M, Magdy N, Sabry N, Farid S (2020) Anticoagulation outcomes in hospitalized Covid-19 patients: a systematic review and meta-analysis of case-control and cohort studies. Rev Med Virol 6:e2180. https:\/\/doi.org\/10.1002\/rmv.2180","journal-title":"Rev Med Virol"},{"key":"504_CR79","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620960797","author":"I Wijaya","year":"2020","unstructured":"Wijaya I, Andhika R, Huang I (2020) The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: a systematic review. Clin Appl Thromb Hemost. https:\/\/doi.org\/10.1177\/1076029620960797","journal-title":"Clin Appl Thromb Hemost"},{"key":"504_CR80","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1097\/MJT.0000000000001295","volume":"27","author":"GK Sridharan","year":"2020","unstructured":"Sridharan GK, Vegunta R, Rokkam VRP et al (2020) Venous thromboembolism in hospitalized COVID-19 patients. Am J Ther 27:e599\u2013e610","journal-title":"Am J Ther"},{"key":"504_CR81","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jacc.2020.08.041","volume":"76","author":"GN Nadkarni","year":"2020","unstructured":"Nadkarni GN, Lala A, Bagiella E et al (2020) Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 76:1815\u20131826","journal-title":"J Am Coll Cardiol"},{"key":"504_CR82","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejim.2020.06.006","volume":"77","author":"R Rossi","year":"2020","unstructured":"Rossi R, Coppi F, Talarico M, Boriani G (2020) Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. Eur J Intern Med 77:158\u2013160","journal-title":"Eur J Intern Med"},{"key":"504_CR83","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2450\/2020.0113-20","volume":"18","author":"A Coppola","year":"2020","unstructured":"Coppola A, Lombardi M, Tassoni MI et al (2020) COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence. Blood Transfus 18:226\u2013229. https:\/\/doi.org\/10.2450\/2020.0113-20","journal-title":"Blood Transfus"},{"key":"504_CR84","doi-asserted-by":"publisher","first-page":"L211","DOI":"10.1152\/ajplung.00199.2020","volume":"319","author":"JA Hippensteel","year":"2020","unstructured":"Hippensteel JA, LaRiviere WB, Colbert JF, Langou\u00ebt-Astri\u00e9 CJ, Schmidt EP (2020) Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol 319:L211\u2013L217. https:\/\/doi.org\/10.1152\/ajplung.00199.2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"504_CR85","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.04.21249227","author":"AH Talasaz","year":"2021","unstructured":"Talasaz AH, Sadeghipour P, Kakavand H et al (2021) Antithrombotic therapy in COVID-19: systematic summary of ongoing or completed randomized trials. medRxiv. https:\/\/doi.org\/10.1101\/2021.01.04.21249227","journal-title":"medRxiv"},{"key":"504_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04870-z","author":"I Cheruiyot","year":"2019","unstructured":"Cheruiyot I, Sehmi P, Ominde B et al (2019) Intracranial hemorrhage in coronavirus disease 2019 (COVID-19) patients. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-020-04870-z","journal-title":"Neurol Sci"},{"issue":"1","key":"504_CR87","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41421-020-00221-6","volume":"6","author":"F Yan","year":"2020","unstructured":"Yan F, Huang F, Xu J et al (2020) Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov 6(1):77. https:\/\/doi.org\/10.1038\/s41421-020-00221-6","journal-title":"Cell Discov"},{"key":"504_CR88","doi-asserted-by":"publisher","first-page":"e017773","DOI":"10.1161\/JAHA.120.019669","volume":"14","author":"J An","year":"2020","unstructured":"An J, Wei R, Zhou H et al (2020) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use and COVID-19 infection among 824,650 patients with hypertension from a US integrated healthcare system. J Am Heart Assoc 14:e017773. https:\/\/doi.org\/10.1161\/JAHA.120.019669","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"504_CR89","doi-asserted-by":"publisher","first-page":"588724","DOI":"10.3389\/fimmu.2020.588724","volume":"30","author":"A Barbieri","year":"2020","unstructured":"Barbieri A, Robinson N, Palma G, Maurea N, Desiderio V, Botti G (2020) Can beta-2-adrenergic pathway be a new target to combat Sars-Cov-2 hyperinflammatory syndrome?\u2014lessons learned from cancer. Front Immunol 30(11):588724. https:\/\/doi.org\/10.3389\/fimmu.2020.588724","journal-title":"Front Immunol"},{"issue":"11","key":"504_CR90","doi-asserted-by":"publisher","first-page":"e2000094","DOI":"10.1002\/bies.202000094","volume":"42","author":"N Vasanthakumar","year":"2020","unstructured":"Vasanthakumar N (2020) Beta-adrenergic blockers as a potential treatment for COVID-19 patients. BioEssays 42(11):e2000094. https:\/\/doi.org\/10.1002\/bies.202000094","journal-title":"BioEssays"},{"key":"504_CR91","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euaa187","author":"N Varma","year":"2021","unstructured":"Varma N, Marrouche NF, Aguinaga L et al (2021) HRS\/EHRA\/APHRS\/LAHRS\/ACC\/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic: developed in partnership with and endorsed by the American college of cardiology (ACC), the American heart association (AHA), the Asia pacific heart rhythm society (APHRS), the European heart rhythm association (EHRA), the heart rhythm society (HRS), and the Latin American heart rhythm society (LAHRS). EP Europace. https:\/\/doi.org\/10.1093\/europace\/euaa187","journal-title":"EP Europace"},{"key":"504_CR92","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/psb.1828","volume":"31","author":"AK Barton","year":"2020","unstructured":"Barton AK, McGowan M, Smyth A, Wright GA, Gardner RS (2020) Classification and choice of antiarrhythmic therapies. Prescriber 31:11\u201317","journal-title":"Prescriber"},{"key":"504_CR93","doi-asserted-by":"publisher","first-page":"421","DOI":"10.5603\/CJ.a2020.0090","volume":"27","author":"EP Navarese","year":"2020","unstructured":"Navarese EP, Musci RL, Frediani L, Gurbel PA (2020) Ion channel inhibition against COVID-19: a novel target for clinical investigation. Cardiol J 27:421\u2013424","journal-title":"Cardiol J"},{"key":"504_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ceca.2009.05.005","volume":"46","author":"Y Zhou","year":"2009","unstructured":"Zhou Y, Frey TK, Yang JJ (2009) Viral calciomics: Interplays between Ca2+ and virus. Cell Calcium 46:1\u201317","journal-title":"Cell Calcium"},{"issue":"1","key":"504_CR95","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/cells901009","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Cao R, Zhong W (2019) Host calcium channels and pumps in viral infections. Cells 9(1):94. https:\/\/doi.org\/10.3390\/cells901009","journal-title":"Cells"},{"key":"504_CR96","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.13.20211953","author":"A Israel","year":"2020","unstructured":"Israel A, Schaffer A, Cicurel A et al (2020) Large population study identifies drugs associated with reduced COVID-19 severity. Medrivx. https:\/\/doi.org\/10.1101\/2020.10.13.20211953","journal-title":"Medrivx"},{"key":"504_CR97","doi-asserted-by":"publisher","unstructured":"Singh S, Florez H (2020) Bioinformatic study to discover natural molecules with activity against COVID-19 [version 1; peer review: 2 approved]. F1000Research 9:1203. https:\/\/doi.org\/10.12688\/f1000research.26731.1","DOI":"10.12688\/f1000research.26731.1"},{"key":"504_CR98","doi-asserted-by":"publisher","unstructured":"Sanchis-Gomar FA-O, Lavie CJ, Morin DP, Perez-Quilis C, Laukkanen JA, Perez MV (2020) Amiodarone in the COVID-19 Era: Treatment for symptomatic patients only, or drug to prevent infection? (1179\u2013187X (Electronic)). Am J Cardiovasc Drugs 1\u20136. https:\/\/doi.org\/10.1007\/s40256-020-00429-7","DOI":"10.1007\/s40256-020-00429-7"},{"key":"504_CR99","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1161\/CIRCULATIONAHA.109.858027","volume":"120","author":"C Patel","year":"2009","unstructured":"Patel C, Yan GX, Kowey PR (2009) Dronedarone Circulation 120:636\u2013644","journal-title":"Dronedarone Circulation"},{"key":"504_CR100","doi-asserted-by":"publisher","unstructured":"Cho J, Lee YJ, Kim JH, et al. Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. Research Square (Preprint) 100. https:\/\/doi.org\/10.21203\/rs.3.rs-34731\/v1","DOI":"10.21203\/rs.3.rs-34731\/v1"},{"key":"504_CR101","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.tcm.2020.08.002","volume":"30","author":"AS Manolis","year":"2020","unstructured":"Manolis AS, Manolis AA, Manolis TA, Apostolopoulos EJ, Papatheou D, Melita H (2020) COVID-19 infection and cardiac arrhythmias. Trends Cardiovasc Med 30:451\u2013460","journal-title":"Trends Cardiovasc Med"},{"key":"504_CR102","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/europace\/eux373","volume":"20","author":"G-A Dan","year":"2018","unstructured":"Dan G-A, Martinez-Rubio A, Agewall S et al (2018) Antiarrhythmic drugs\u2014clinical use and clinical decision making: a consensus document from the European heart rhythm association (EHRA) and European society of cardiology (ESC) working group on cardiovascular pharmacology, endorsed by the heart rhythm society (HRS), Asia-Pacific heart rhythm society (APHRS) and international society of cardiovascular pharmacotherapy (ISCP). EP Europace 20:731\u2013732","journal-title":"EP Europace"},{"key":"504_CR103","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-020-00608-2","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F (2020) Antidiabetes agents against Sars-Cov-2 infection. SN Compr Clin Med. https:\/\/doi.org\/10.1007\/s42399-020-00608-2","journal-title":"SN Compr Clin Med"},{"key":"504_CR104","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.dsx.2020.04.004","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Gupta R, Ghosh A, Misra A (2020) Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 14:303\u2013310. https:\/\/doi.org\/10.1016\/j.dsx.2020.04.004","journal-title":"Diabetes Metab Syndr"},{"key":"504_CR105","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.therap.2020.05.006","volume":"75","author":"Bouhanick B, Cracowski JL, Faillie JL; French Society of Pharmacology, Therapeutics (SFPT)","year":"2020","unstructured":"Bouhanick B, Cracowski JL, Faillie JL; French Society of Pharmacology, Therapeutics (SFPT) (2020) Diabetes and COVID-19. Therapie 75:327\u2013333. https:\/\/doi.org\/10.1016\/j.therap.2020.05.006","journal-title":"Therapie"},{"key":"504_CR106","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","volume":"8","author":"SR Bornstein","year":"2020","unstructured":"Bornstein SR, Rubino F, Khunti K et al (2020) Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 8:546\u2013550. https:\/\/doi.org\/10.1016\/S2213-8587(20)30152-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"504_CR107","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/dc20-0660","volume":"43","author":"Y Chen","year":"2020","unstructured":"Chen Y, Yang D, Cheng B et al (2020) Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 43:1399\u20131407. https:\/\/doi.org\/10.2337\/dc20-0660","journal-title":"Diabetes Care"},{"key":"504_CR108","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s00125-020-05180-x","volume":"63","author":"Cariou B, Hadjadj S, Wargny M, et al.; CORONADO investigators","year":"2020","unstructured":"Cariou B, Hadjadj S, Wargny M, et al.; CORONADO investigators (2020) Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 63:1500\u20131515. https:\/\/doi.org\/10.1007\/s00125-020-05180-x (Erratum in: Diabetologia. 2020 Jul 2)","journal-title":"Diabetologia"},{"key":"504_CR109","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.19.20135095","author":"C Bramante","year":"2020","unstructured":"Bramante C, Ingraham N, Murray T et al (2020) Observational study of metformin and risk of mortality in patients hospitalized with Covid-19. medRxiv. https:\/\/doi.org\/10.1101\/2020.06.19.20135095 (Preprint)","journal-title":"medRxiv"},{"issue":"20","key":"504_CR110","doi-asserted-by":"publisher","first-page":"30924","DOI":"10.1016\/j.jamda.2020.10.031","volume":"S1525\u20138610","author":"MA Lally","year":"2020","unstructured":"Lally MA, Tsoukas P, Halladay CW, O\u2019Neill E, Gravenstein S, Rudolph JL (2020) Metformin is associated with decreased 30\u00a0day mortality among nursing home residents infected with SARS-CoV2. J Am Med Dir Assoc S1525\u20138610(20):30924\u201330925. https:\/\/doi.org\/10.1016\/j.jamda.2020.10.031","journal-title":"J Am Med Dir Assoc"},{"key":"504_CR111","doi-asserted-by":"publisher","first-page":"108268","DOI":"10.1016\/j.diabres.2020.108268","volume":"165","author":"AK Singh","year":"2020","unstructured":"Singh AK, Singh R (2020) Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19? Diabetes Res Clin Pract 165:108268. https:\/\/doi.org\/10.1016\/j.diabres.2020.108268 (Epub 2020 Jun 10)","journal-title":"Diabetes Res Clin Pract"},{"key":"504_CR112","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.diabet.2020.07.006","volume":"46","author":"AJ Scheen","year":"2020","unstructured":"Scheen AJ (2020) Metformin and COVID-19: from cellular mechanisms to reduced mortality. Diabetes Metab 46:423\u2013426. https:\/\/doi.org\/10.1016\/j.diabet.2020.07.006","journal-title":"Diabetes Metab"},{"key":"504_CR113","doi-asserted-by":"publisher","first-page":"582936","DOI":"10.3389\/fendo.2020.582936","volume":"11","author":"H Muniangi-Muhitu","year":"2020","unstructured":"Muniangi-Muhitu H, Akalestou E, Salem V, Misra S, Oliver NS, Rutter GA (2020) Covid-19 and diabetes: a complex bidirectional relationship. Front Endocrinol (Lausanne) 11:582936. https:\/\/doi.org\/10.3389\/fendo.2020.582936","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"504_CR114","doi-asserted-by":"publisher","first-page":"bnaa011","DOI":"10.1210\/endrev\/bnaa011","volume":"41","author":"DJ Drucker","year":"2020","unstructured":"Drucker DJ (2020) Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev 41(3):bnaa011. https:\/\/doi.org\/10.1210\/endrev\/bnaa011","journal-title":"Endocr Rev"},{"issue":"11","key":"504_CR115","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/jdi.13326","volume":"2020","author":"YJ Chee","year":"2020","unstructured":"Chee YJ, Tan SK, Yeoh E (2020) Dissecting the interaction between COVID-19 and diabetes mellitus. J Diabetes Invest 2020(11):1104\u20131114. https:\/\/doi.org\/10.1111\/jdi.13326","journal-title":"J Diabetes Invest"},{"key":"504_CR116","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.dsx.2020.04.040","volume":"14","author":"A Nakhleh","year":"2020","unstructured":"Nakhleh A, Shehadeh N (2020) Interactions between antihyperglycemic drugs and the renin-angiotensin system: putative roles in COVID-19. A mini-review. Diabetes Metab Syndr 14:509\u2013512. https:\/\/doi.org\/10.1016\/j.dsx.2020.04.040","journal-title":"Diabetes Metab Syndr"},{"key":"504_CR117","doi-asserted-by":"publisher","first-page":"108146","DOI":"10.1016\/j.diabres.2020.108146","volume":"163","author":"R Pal","year":"2020","unstructured":"Pal R, Bhadada SK (2020) Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract 163:108146. https:\/\/doi.org\/10.1016\/j.diabres.2020.108146","journal-title":"Diabetes Res Clin Pract"},{"key":"504_CR118","doi-asserted-by":"publisher","unstructured":"Rhee SY, Lee J, Nam H, Kyoung D-S, Kim DJ (2020)\u00a0Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. Diabet  Metabol J 118. https:\/\/doi.org\/10.4093\/dmj.2020.0206","DOI":"10.4093\/dmj.2020.0206"},{"key":"504_CR119","doi-asserted-by":"publisher","first-page":"108444","DOI":"10.1016\/j.diabres.2020.108444","volume":"171","author":"R Strollo","year":"2020","unstructured":"Strollo R, Maddaloni E, Dauriz M, Pedone C, Buzzetti R, Pozzilli P (2020) Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. Diab Res Clin Pract 171:108444. https:\/\/doi.org\/10.1016\/j.diabres.2020.108444","journal-title":"Diab Res Clin Pract"},{"key":"504_CR120","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/dom.14097","volume":"22","author":"GP Fadini","year":"2020","unstructured":"Fadini GP, Morieri ML, Longato E et al (2020) Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: a case-control study. Diabetes ObesityMetab 22:1946\u20131950. https:\/\/doi.org\/10.1111\/dom.14097","journal-title":"Diabetes ObesityMetab"},{"issue":"10","key":"504_CR121","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.3390\/ijerph17103664","volume":"17","author":"M Mirabelli","year":"2020","unstructured":"Mirabelli M, Chiefari E, Puccio L, Foti DP, Brunetti A (2020) Potential benefits and harms of novel antidiabetic drugs during COVID-19 crisis. Int J Environ Res Public Health 17(10):3664. https:\/\/doi.org\/10.3390\/ijerph17103664","journal-title":"Int J Environ Res Public Health"},{"key":"504_CR122","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/1932296820932155","volume":"14","author":"T Koufakis","year":"2020","unstructured":"Koufakis T, Metallidis S, Zebekakis P, Ajjan RA, Kotsa K (2020) Sodium-glucose cotransporter 2 inhibitors in the era of COVID-19 pandemic: is the benefit to risk ratio still favorable? J Diab Sci Techn 14:745\u2013747. https:\/\/doi.org\/10.1177\/1932296820932155","journal-title":"J Diab Sci Techn"},{"issue":"1068\u201377","key":"504_CR123","first-page":"e3","volume":"31","author":"L Zhu","year":"2020","unstructured":"Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J et al (2020) Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 31(1068\u201377):e3","journal-title":"Cell Metab"},{"key":"504_CR124","unstructured":"Bouillon R. Vitamin D and extraskeletal health. UpToDate Accessed on December 2020. https:\/\/www.uptodate.com\/contents\/vitamin-d-and-extraskeletal-health"},{"key":"504_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00051-6","author":"DA Jolliffe","year":"2021","unstructured":"Jolliffe DA, Camargo CA, Sluyter JD et al (2021) Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrin. https:\/\/doi.org\/10.1016\/S2213-8587(21)00051-6","journal-title":"Lancet Diabetes Endocrin"},{"key":"504_CR126","doi-asserted-by":"publisher","first-page":"n544","DOI":"10.1136\/bmj.n544","volume":"372","author":"K Vimaleswaran","year":"2021","unstructured":"Vimaleswaran K, Forouhi NG, Khunti K (2021) Vitamin D and covid-19. BMJ 372:n544. https:\/\/doi.org\/10.1136\/bmj.n544","journal-title":"BMJ"},{"key":"504_CR127","doi-asserted-by":"publisher","first-page":"154276","DOI":"10.1016\/j.metabol.2020.154276","volume":"109","author":"M Chakhtoura","year":"2020","unstructured":"Chakhtoura M, Napoli N, El Hajj FG (2020) Commentary: myths and facts on vitamin D amidst the COVID-19 pandemic. Metabolism 109:154276. https:\/\/doi.org\/10.1016\/j.metabol.2020.154276","journal-title":"Metabolism"},{"key":"504_CR128","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S2213-8587(20)30268-0","volume":"8","author":"AR Martineau","year":"2020","unstructured":"Martineau AR, Forouhi NG (2020) Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrin 8:735\u2013736","journal-title":"Lancet Diabetes Endocrin"},{"key":"504_CR129","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13158","author":"P Bergman","year":"2020","unstructured":"Bergman P (2020) The link between vitamin D and COVID-19: distinguishing facts from fiction. J Intern Med. https:\/\/doi.org\/10.1111\/joim.13158","journal-title":"J Intern Med"},{"key":"504_CR130","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jiph.2020.06.021","volume":"13","author":"N Ali","year":"2020","unstructured":"Ali N (2020) Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health 13:1373\u20131380","journal-title":"J Infect Public Health"},{"key":"504_CR131","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3389\/fimmu.2020.01523","volume":"11","author":"JF Arboleda","year":"2020","unstructured":"Arboleda JF, Urcuqui-Inchima S (2020) Vitamin D supplementation: a potential approach for coronavirus\/COVID-19 therapeutics? Front Immun 11:1523","journal-title":"Front Immun"},{"key":"504_CR132","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqaa381","author":"H Ma","year":"2021","unstructured":"Ma H, Zhou T, Heianza Y, Qi L (2021) Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank. Am J Clin Nutr. https:\/\/doi.org\/10.1093\/ajcn\/nqaa381","journal-title":"Am J Clin Nutr"},{"key":"504_CR133","doi-asserted-by":"publisher","first-page":"105751","DOI":"10.1016\/j.jsbmb.2020.105751.pmid:32871238","volume":"203","author":"M Entrenas Castillo","year":"2020","unstructured":"Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM et al (2020) Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol 203:105751. https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105751.pmid:32871238","journal-title":"J Steroid Biochem Mol Biol"},{"key":"504_CR134","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2020-139065","author":"A Rastogi","year":"2020","unstructured":"Rastogi A, Bhansali A, Khare N et al (2020) Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). Postgrad Med J. https:\/\/doi.org\/10.1136\/postgradmedj-2020-139065","journal-title":"Postgrad Med J"},{"key":"504_CR135","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26848","author":"IH Murai","year":"2021","unstructured":"Murai IH, Fernandes AL, Sales LP et al (2021) Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe covid-19: a randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.26848","journal-title":"JAMA"},{"key":"504_CR136","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1186\/s13063-020-04928-5","volume":"21","author":"Annweiler C, Beaudenon M, Gautier J, et al. COVIT-TRIAL study group","year":"2020","unstructured":"Annweiler C, Beaudenon M, Gautier J, et al. COVIT-TRIAL study group (2020) COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial. Trials 21:1031. https:\/\/doi.org\/10.1186\/s13063-020-04928-5","journal-title":"Trials"},{"key":"504_CR137","doi-asserted-by":"publisher","first-page":"105719","DOI":"10.1016\/j.jsbmb.2020.105719","volume":"202","author":"JM Quesada-Gomez","year":"2020","unstructured":"Quesada-Gomez JM, Entrenas-Castillo M, Bouillon R (2020) Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: revised Ms SBMB 2020_166. J Steroid Biochem Mol Biol 202:105719","journal-title":"J Steroid Biochem Mol Biol"},{"key":"504_CR138","doi-asserted-by":"publisher","first-page":"P23","DOI":"10.1530\/EJE-18-0736","volume":"180","author":"P Lips","year":"2019","unstructured":"Lips P, Cashman KD, Lamberg-Allardt C et al (2019) Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European calcified tissue society. Eur J Endocrinol 180:P23\u2013P54","journal-title":"Eur J Endocrinol"},{"key":"504_CR139","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:e21","journal-title":"Lancet Respir Med"},{"key":"504_CR140","unstructured":"World Health Organization. Based on currently available information, WHO does not recommend against the use of ibuprofen. Geneva: WHO;\u00a02020. Available from:\u00a0https:\/\/twitter.com\/WHO\/status\/1240409217997189128 [Accessed 22 April 2020]."},{"issue":"9","key":"504_CR141","doi-asserted-by":"publisher","first-page":"e1003308","DOI":"10.1371\/journal.pmed.1003308","volume":"17","author":"LC Lund","year":"2020","unstructured":"Lund LC, Kristensen KB, Reilev M et al (2020) Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study. PLoS Med 17(9):e1003308. https:\/\/doi.org\/10.1371\/journal.pmed.1003308","journal-title":"PLoS Med"},{"key":"504_CR142","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14514","author":"R Vaja","year":"2020","unstructured":"Vaja R, Kai Chan JS, Ferreira P et al (2020) The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.14514","journal-title":"Br J Clin Pharmacol"},{"key":"504_CR143","first-page":"m1185","volume":"368","author":"P Ioannou","year":"2020","unstructured":"Ioannou P (2020) Re: Non-steroidal anti-inflammatory drugs and Covid-19; an ambiguous correlation. BMJ 368:m1185","journal-title":"BMJ"},{"key":"504_CR144","first-page":"m1185","volume":"368","author":"R Rothstein","year":"2020","unstructured":"Rothstein R, Leibowitz JS, Benjamin S (2020) Re: Non-steroidal anti-inflammatory drugs and Covid-19. BMJ 368:m1185","journal-title":"BMJ"},{"key":"504_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40256-020-00459-1","volume":"28","author":"S Kaul","year":"2020","unstructured":"Kaul S, Gupta M, Bandyopadhyay D et al (2020) Gout pharmacotherapy in cardiovascular diseases: a review of utility and outcomes. Am J Cardiovasc Drugs 28:1\u201314. https:\/\/doi.org\/10.1007\/s40256-020-00459-1","journal-title":"Am J Cardiovasc Drugs"},{"key":"504_CR146","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13488","author":"TI Hariyanto","year":"2021","unstructured":"Hariyanto TI, Halim DA, Jodhinata C, Yanto TA, Kurniawan A (2021) Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Clin Exp Pharmacol Physiol. https:\/\/doi.org\/10.1111\/1440-1681.13488","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"504_CR147","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.26.21250494","author":"Tardif JC, Bouabdallaoui N, L\u2019Allier PL, et al; for the COLCORONA Investigators","year":"2021","unstructured":"Tardif JC, Bouabdallaoui N, L\u2019Allier PL, et al; for the COLCORONA Investigators (2021) Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv. https:\/\/doi.org\/10.1101\/2021.01.26.21250494","journal-title":"medRxiv"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-021-00504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-021-00504-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-021-00504-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T03:51:33Z","timestamp":1627530693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-021-00504-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":147,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1007\/s41999-021-00504-5","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"20 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Other authors report no further conflicts of interest related to this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}